Bone Marrow Aspirate Concentrate Injections

Autologous bone marrow aspirate concentrate injections attempt to harness the regenerative power of your body's own stem cells as a treatment option for degenerative orthopedic conditions. TSAOG Orthopaedics is happy to offer bone marrow aspirate concentrate injections in San Antonio, TX.

Bone Marrow Aspirate Concentrate (BMAC) Injections孤独老祖 论开挂的正确姿势 快穿 小说 孤独老祖 论开挂的正确姿势 快穿 小说 ,山达基教 山达基教最新章节免费阅读 山达基教 山达基教最新章节免费阅读 ,旧时燕飞帝王家 旧时燕飞帝王家最新章节免费在线阅读 旧时燕飞帝王家 旧时燕飞帝王家最新章节免费在线阅读

TSAOG Orthopaedics is now performing bone marrow aspirate concentrate (BMAC) injections in San Antonio, TX. We are excited to offer this autologous therapy, which embraces the regenerative power of mesenchymal stem cells to give patients another treatment option for dealing with orthopedic conditions such as osteoarthritis and other degenerative joint conditions. 


You May Benefit From BMAC Injections If You Have:

  • Avascular Necrosis
  • Bone Loss
  • Cartilage Defects
  • Degenerative Joint Changes, Including Osteoarthritis
  • Disc-related Back Pain
  • Meniscus Tears
  • Non-Union Fractures
  • Osteonecrosis
  • Tendonopathies


What is a Stem Cell?

Most cells in the human body have an assigned purpose. They are liver cells, fat cells, bone cells, and so on. These cells can replicate more of their own kind of cell, but they cannot differentiate into another kind of cell.

Stem cells are the primitive cells from which all other cells developed. They are undifferentiated cells with the ability not only to self-replicate, but to specialize to become different types of human cells. There are several types of stem cells, but the kinds used in BMAC therapy are called mesenchymal stem cells (MSCs).

An MSC is a cell with strong potential for tissue repair because it can:

  • Self-replicate
  • Reduce inflammation
  • Combat cell death
  • Differentiate into more than one specialized cell of the body (including bone cells, muscle cells, cartilage cells, and fat cells)

In medical research, tissues such as muscles, cartilage, tendons, ligaments, and vertebral discs have shown some capacity for self repair. As a result, tissue engineering and the use of mesenchymal cells and/or bio-active molecules such as growth factors are being tested and studied to determine the role they can play in tissue regeneration and tissue repair.

孤独老祖 论开挂的正确姿势 快穿 小说 孤独老祖 论开挂的正确姿势 快穿 小说 ,山达基教 山达基教最新章节免费阅读 山达基教 山达基教最新章节免费阅读 ,旧时燕飞帝王家 旧时燕飞帝王家最新章节免费在线阅读 旧时燕飞帝王家 旧时燕飞帝王家最新章节免费在线阅读


How Does BMAC Therapy Work?

Mesenchymal stem cells (MSCs) are adult stem cells that can be found in bone marrow. TSAOG Orthopaedics performs autologous BMAC therapy, which means that the cells used in your treatment are taken from your own body, not from a donor. Using your own cells for the procedure helps reduce your risk of infection and eliminate the possibility of immune rejection.

In an autologous BMAC procedure, your physician will draw a sample of bone marrow from the iliac crest of your hip. The sample is then filtered and concentrated in a sterile environment, then injected into the area of your body that you are trying to heal. This procedure is done on an outpatient basis while under sedation and leaves no scarring.

The idea behind BMAC therapy is that the injection of these concentrated regenerative cells at an area of your body experiencing degeneration will kick start your body's ability to heal itself. These injections can be given independently or in conjunction with an orthopedic surgical procedure.

Dr. Frank Garcia discusses the use of BMAC therapy in the treatment of osteoarthritis.

Orthopedic Areas of Interest for BMAC Therapy

  • Articular Cartilage – Damage to the articular cartilage following an injury has poor potential for repair and can lead to arthritic changes many years after injury. Recent studies have shown favorable outcomes and better knee scores at 2 year follow up for bone marrow derived mesenchymal cells compared to current techniques of microfracture and autologous chondrocyte implantation.
  • Bone – Trauma and some pathological conditions can lead to extensive bone loss, which requires transplantation of bone and other bone substitutes to restore structural integrity. A large number of studies have shown great potential for mesenchymal cells to repair critically sized bone defects, noting better bone growth and more robust bone formation than controlled groups.
  • Tendons and Ligaments – Injuries to tendons and ligaments heal by forming inferior quality tissue. Autografts, allografts, and resorbable materials have been used to repair defects in tendons and ligaments, but these carry risks including donor site morbidity, scar formation, and tissue rejection. A number of studies on the use of mesenchymal stem cells to improve the repair of tendons and tendon defects have been carried out with favorable results when measured in histology and tissue strength. The use of mesenchymal cells with tissue allografts enhances the graft and improves the biomechanical properties compared to control studies.
  • Meniscus – Most tears of the meniscus occur in avascular zones with little or no potential for repair. Standard biological healing processes produce limited results and meniscectomy (removal of all or part of the torn meniscus) has been shown to have a strong association with subsequent development of osteoarthritis. Recently, studies have shown that self-paced therapy including mesenchymal stem cells demonstrates biological healing and adherence of meniscal tears in avascular zones.
  • Spine – Degeneration of intervertebral discs is a common cause of back pain and morbidity. Most patients are treated conservatively with improvement in approximately 90%. If conservative treatment proves ineffective, the surgical options for discogenic back pain are limited and usually invasive. Cell-based tissue treatments, including mesenchymal stem cell injections for degenerative disc subjects have been shown to diminish the incidence of low back pain, with clinical results noting improvement in back pain and MRI results showing regeneration of disc tissue. In cases where spinal fusions are necessary, the use of stem cells through bone marrow aspirate has shown greater success in obtaining fusion through bone formation as compared to standard fusion techniques.
  • Osteonecrosis – Osteonecrosis or avascular ischemia of the hip can be associated with progression to an advanced arthritic joint. Standard treatment for osteonecrosis has included cord decompression with limited results. Studies report improvement in hip scores in patients treated with mesenchymal stem cells and cord decompression versus cord decompression alone.

What to Expect with a Stand Alone BMAC Procedure:

  • Initial Visit – An initial consultation with your physician will be required to find out if you are a candidate for BMAC Therapy. In some cases, an MRI may be recommended to confirm your diagnosis and rule out any underlying conditions that could cause complications. If you are determined to be a candidate for BMAC Therapy, your procedure will be scheduled for another day. This initial consultation is usually covered by your insurance plan.
  • Preparation – For two weeks prior to your procedure, do not take aspirin or anti-inflammatory medications (NSAIDS).
  • Procedure – Stand alone BMAC therapy is done as an outpatient procedure, so most patients will leave the clinic and resume low impact activities the same day. Some patients have reported mild pain for 48-72 hours after their procedure, but this can often be attributed to the absence of their routine anti-inflammatory medications. After this time period, most patients will experience a gradual decrease in pain and some may begin to notice increased function.
  • Post-Procedure – To give your procedure the best chance to provide lasting results, our physicians recommend the following post-procedure restrictions:
    • Do not take anti-inflammatory medication for 2 weeks after your procedure.
    • Rest for the first 24-48 hours after your procedure.
    • Restrict the treated joint to low impact / general use for the first 2 weeks.
    • For weeks 3-4, you may resume walking, cardio, and light lifting.
    • After 4 weeks, you may resume running and weightlifting.
    • Pay special attention to the treated joint and contact your physician with any questions or concerns you may have.

Please Note: If you are having a BMAC therapy procedure in conjunction with another surgical procedure, your recommendations may change. Consult with your physician on the guidelines and restrictions for your specific case.

Is BMAC Therapy Covered By My Insurance?

No. Because BMAC injections are considered investigational for orthopedic applications, most insurance companies will not cover the cost. Please contact our office to discuss cash payment options. 

What is the Cost of BMAC Therapy?

Your out-of-pocket cost will vary, depending upon whether you have BMAC therapy independent of or in conjunction with another surgical procedure.
Our current pricing for BMAC therapy is as follows:

  • BMAC therapy on one area as a stand alone procedure will be $3,600, which includes anesthesia.
  • BMAC therapy on bilateral areas as a stand alone procedure will be $4,600, which includes anesthesia.
  • BMAC therapy on one area in conjunction with a surgical procedure will be $2,600. Anesthesia will be billed for the surgical procedure, not for the BMAC therapy, in this case.
  • BMAC therapy on bilateral areas in conjunction with a surgical procedure will be $3,200. Anesthesia will be billed for the surgical procedure, not for the BMAC therapy, in this case.


1. Fu, Tsai-Sheng, et al, Enhancement of Posterolateral Lumbar Spine Fusion Using Low-Dose rhBMP-2 and Cultured Marrow Stromal Cells, Journal of Orthopaedic Research March 2009, 380-4.
2. Centeno, Christopher, et al, Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells, Medical Hypotheses (2008) 71, 900–908.
3. Kovacevic BS, David et al, Biological Augmentation of Rotator Cuff Tendon Repair, Clin Orthop Relat Res (2008) 466:622–633.
4. Rotini, Roberto et al, New perspectives in rotator cuff tendon regeneration: review of tissue engineered therapies, Chir Organi Mov (2008) 91:87–92.
5. Tow B., et al, Disc Regeneration: A Glimpse of the Future, 2007 The Congress of 128 Neurological Surgeons.
6. Chen, Faye, et al, Technology Insight: adult stem cells in cartilage regeneration and tissue engineering, NATURE CLINICAL PRACTICE RHEUMATOLOGY, JULY 2006 VOL 2 NO 7, 373-382.
7. Zantop, Thore et al, Extracellular Matrix Scaffolds Are Repopulated by Bone Marrow-Derived Cells in a Mouse Model of Achilles Tendon Reconstruction, Journal of Orthopaedic Research June 2006, 1299-1309.
8. Acosta F., Lotz J., Ames C., et al, The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview, Neurosurg Focus 19 (3):E4, 2005.
9. Baksh D., et al, Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy, J. Cell. Mol. Med. Vol 8, No 3, 2004 pp. 301-316.
10. Crevesten G., et al, Intervertebral Disc Cell Therapy for Regeneration: Mesenchymal Stem Cell Implantation in Rat Intervertebral Discs, Annals of Biomedical Engineering, Vol. 32, No. 3, March 2004 pp. 430–434.
11. Hicok, K. C., et al, Human adipose-derived adult stem cells produce osteoid in vivo, Tissue Engineering, Vol. 10(3-4), 371-80, 2004.
12. Javazon, E., Mesenchymal stem cells paradoxes of passaging, Expiremental Hematology, 32(5)- 414-25, 2004.
13. Loening, A. M., et al, AMIDE: A Free Software Tool for Multimodality Medical Image Analysis, Molecular Imaging, Vol. 2(3), 131-7, 2003.
14. Heck J., et al, A Classification System for the Assessment of Lumbar Pain in Athletes, Journal of Athletic Training 2000;35(2):204–211.
15. Kraus, K., Critically sized osteo-periosteal femoral defects: a dog model, Journal of Investigative Surgery, Vol. 12(2), 115-24, 1999.
16. Hernigou, Philippe et al, Abnormalities in the Bone Marrow of the Iliac Crest in Patients Who Have Osteonecrosis Secondary to Corticosteroid Therapy or Alcohol Abuse, J Bone Joint Surg Am. 1997;79:1047-53.
17. Nakajima MD, Takashi, et al, Evaluation of Posterolateral Spinal Fusion Using Mesenchymal Stem Cells, SPINE Volume 32, Number 22, pp 2432–2436.